Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Class I Histone Deacetylases in a “Complex” Environment
Christopher J. Millard, Peter J. Watson, Louise Fairall, et al.
Trends in Pharmacological Sciences (2017) Vol. 38, Iss. 4, pp. 363-377
Closed Access | Times Cited: 160

Showing 1-25 of 160 citing articles:

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
Carlos Moreno–Yruela, Di Zhang, Wei Wei, et al.
Science Advances (2022) Vol. 8, Iss. 3
Open Access | Times Cited: 336
Chalcone Derivatives: Promising Starting Points for Drug Design
Marcelo do Nascimento Gomes, Eugene Muratov, Maristela Pereira, et al.
Molecules (2017) Vol. 22, Iss. 8, pp. 1210-1210
Open Access | Times Cited: 335
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
Giorgio Milazzo, Daniele Mercatelli, Giulia Di Muzio, et al.
Genes (2020) Vol. 11, Iss. 5, pp. 556-556
Open Access | Times Cited: 272
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke, Nina Reßing, Finn K. Hansen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 137
Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target
Severin Lechner, Martin Ian P. Malgapo, Christian Grätz, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 8, pp. 812-820
Open Access | Times Cited: 74
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
Rashmi R. Shah
Drug Safety (2019) Vol. 42, Iss. 2, pp. 235-245
Closed Access | Times Cited: 138
Histone deacetylase function in CD4+ T cells
Wilfried Ellmeier, Christian Seiser
Nature reviews. Immunology (2018) Vol. 18, Iss. 10, pp. 617-634
Closed Access | Times Cited: 129
Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo
R. D. W. Kelly, Aditya Chandru, P. J. Watson, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 118
Co-repressor, co-activator and general transcription factor: the many faces of the Sin3 histone deacetylase (HDAC) complex
Grace E. Adams, Aditya Chandru, Shaun M. Cowley
Biochemical Journal (2018) Vol. 475, Iss. 24, pp. 3921-3932
Open Access | Times Cited: 109
Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST Complex
Yun Song, Lisbeth Dagil, Louise Fairall, et al.
Cell Reports (2020) Vol. 30, Iss. 8, pp. 2699-2711.e8
Open Access | Times Cited: 109
Loss of HDAC3 results in nonreceptive endometrium and female infertility
Tae Hoon Kim, Jung‐Yoon Yoo, Kyung‐Chul Choi, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 474
Open Access | Times Cited: 108
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Flávia Alves Verza, Umashankar Das, Ana Lúcia Fachin, et al.
Cancers (2020) Vol. 12, Iss. 6, pp. 1664-1664
Open Access | Times Cited: 105
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
Joshua P. Smalley, Grace E. Adams, Christopher J. Millard, et al.
Chemical Communications (2020) Vol. 56, Iss. 32, pp. 4476-4479
Open Access | Times Cited: 94
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells
Joshua P. Smalley, India M. Baker, Wiktoria A. Pytel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5642-5659
Open Access | Times Cited: 56
Chiral Posttranslational Modification to Lysine ε-Amino Groups
Carlos Moreno–Yruela, Michael Bæk, Fabrizio Monda, et al.
Accounts of Chemical Research (2022) Vol. 55, Iss. 10, pp. 1456-1466
Closed Access | Times Cited: 42
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
Antonio Curcio, Roberta Rocca, Stefano Alcaro, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 620-620
Open Access | Times Cited: 15
Histone deacetylase complexes: Structure, regulation and function
Moges Dessale Asmamaw, 阿形 清和, Lirong Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189150-189150
Closed Access | Times Cited: 14
Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders
Felix Feller, Irina Honin, Martina Miranda, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Discovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor
Sanil Bhatia, Viktoria Krieger, M. Groll, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 22, pp. 10299-10309
Open Access | Times Cited: 75
Complex neuroprotective and neurotoxic effects of histone deacetylases
Elizabeth A. Thomas, Santosh R. D’Mello
Journal of Neurochemistry (2018) Vol. 145, Iss. 2, pp. 96-110
Open Access | Times Cited: 67
Histone/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation
L. Wang, Ulf H. Beier, Tatiana Akimova, et al.
American Journal of Transplantation (2018) Vol. 18, Iss. 7, pp. 1596-1603
Open Access | Times Cited: 60
Diverse nucleosome Site-Selectivity among histone deacetylase complexes
Zhipeng A. Wang, Christopher J. Millard, Chia‐Liang Lin, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 58
KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1
Jianbin Ma, Ji‐Yu Bai, Haibao Zhang, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 6
Open Access | Times Cited: 54
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy
Manasa Gangadhar Shetty, Padmini Pai, Renita Esther Deaver, et al.
Pharmacological Research (2021) Vol. 170, pp. 105695-105695
Closed Access | Times Cited: 52
Characterization of Histone Deacetylase Mechanisms in Cancer Development
Rihan Hai, Liuer He, Guang Shu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top